Catalent Pharma Solutions has been steadily expanding its manufacturing capabilities around the world and is now set to beef up in the center of the U.S. The move will add more than 230 jobs to its operation in Kansas City, MO.
|Scott Houlton--Courtesy of Catalent|
The pharma services company's Kansas City facility is a multiservice operation, offering drug development and manufacturing from clinical supply to commercial scale. The company said in an emailed statement that it is expanding both development and manufacturing capabilities there. It said it expects the expansion to be completed this year.
"This site has been successful in putting products through the development cycle, and our customer branch is interested in having a turnkey solution," Scott Houlton, Catalent's president of development and clinical services, told the Kansas City Business Journal. "When we are developing products, they want to stay here to do the commercial manufacturing rather than moving somewhere else. That's why Kansas City is a logical choice."
The office of Missouri Gov. Jay Nixon said Catalent's investment will run to more than $30 million and add more than 230 jobs to the facility. That is 236 jobs to be exact, according to the Business Journal, which says the project will get $2.65 million in state money by meeting job and investment goals.
The company, which is prepping for an initial public offering, won a similar level of state support from Kentucky last year for investing $35 million to expand a facility in Winchester and adding about 90 workers. Catalent also did a couple of deals in China last year, including forming a joint venture with ShangPharma to build a 31,000-square-foot plant in Shanghai.
- read the Business Journal story
- more from the state